TY - JOUR
T1 - Polyamine depletion inhibits NF-κB binding to DNA and interleukin-8 production in human chondrocytes stimulated by tumor necrosis factor-α
AU - Facchini, Annalisa
AU - Borzì, Rosa Maria
AU - Marcu, Kenneth B.
AU - Stefanelli, Claudio
AU - Olivotto, Eleonora
AU - Goldring, Mary B.
AU - Facchini, Andrea
AU - Flamigni, Flavio
PY - 2005/9
Y1 - 2005/9
N2 - The activation of the NF-κB pathway by pro-inflammatory cytokines, such as tumor necrosis factor-α (TNFα), can bean important contributor for the re-programming of chondrocyte gene expression, thereby making it a therapeutic target in articular diseases. To search for new approaches to limit cartilage damage, we investigated the requirement of polyamines for NF-κB activation by TNFα in human C-28/12 chondrocytes, using α-difluoromethylornithine (DFMO), a specific polyamine biosynthesis inhibitor. The NF-κB pathway was dissected by using pharmacological inhibitors or by expressing a transdominant IκBα super repressor. Treatment of C-28/12 chondrocytes with TNFα resulted in a rapid enhancement of nuclear localization and DNA binding activity of the p6S NF-κB subunit. TNFα also increased the level and extracellular release of interleukin-8 (IL-8), a CXC chemokine that can have a role in arthritis, in an NF-κB-dependent manner. Pre-treatment of chondrocytes with DFMO, while causing polyamine depletion, significantly reduced NF-κB DNA binding activity. Moreover, DFMO also decreased IL-8 production without affecting cellular viability. Restoration of polyamine levels by the co-addition of putrescine circumvented the inhibitory effects of DFMO. Our results show that the intracellular depletion of polyamines inhibits the response of chondrocytes to TNFα by interfering with the DNA binding activity of NF-κB. This suggests that a pharmacological and/or genetic approach to deplete the polyamine pool in chondrocytes may represent a useful way to reduce NF-κB activation by inflammatory cytokines in arthritis without provoking chondrocyte apoptosis.
AB - The activation of the NF-κB pathway by pro-inflammatory cytokines, such as tumor necrosis factor-α (TNFα), can bean important contributor for the re-programming of chondrocyte gene expression, thereby making it a therapeutic target in articular diseases. To search for new approaches to limit cartilage damage, we investigated the requirement of polyamines for NF-κB activation by TNFα in human C-28/12 chondrocytes, using α-difluoromethylornithine (DFMO), a specific polyamine biosynthesis inhibitor. The NF-κB pathway was dissected by using pharmacological inhibitors or by expressing a transdominant IκBα super repressor. Treatment of C-28/12 chondrocytes with TNFα resulted in a rapid enhancement of nuclear localization and DNA binding activity of the p6S NF-κB subunit. TNFα also increased the level and extracellular release of interleukin-8 (IL-8), a CXC chemokine that can have a role in arthritis, in an NF-κB-dependent manner. Pre-treatment of chondrocytes with DFMO, while causing polyamine depletion, significantly reduced NF-κB DNA binding activity. Moreover, DFMO also decreased IL-8 production without affecting cellular viability. Restoration of polyamine levels by the co-addition of putrescine circumvented the inhibitory effects of DFMO. Our results show that the intracellular depletion of polyamines inhibits the response of chondrocytes to TNFα by interfering with the DNA binding activity of NF-κB. This suggests that a pharmacological and/or genetic approach to deplete the polyamine pool in chondrocytes may represent a useful way to reduce NF-κB activation by inflammatory cytokines in arthritis without provoking chondrocyte apoptosis.
UR - http://www.scopus.com/inward/record.url?scp=19444380095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19444380095&partnerID=8YFLogxK
U2 - 10.1002/jcp.20368
DO - 10.1002/jcp.20368
M3 - Article
C2 - 15828019
AN - SCOPUS:19444380095
VL - 204
SP - 956
EP - 963
JO - Journal of cellular and comparative physiology
JF - Journal of cellular and comparative physiology
SN - 0021-9541
IS - 3
ER -